Key facts
| Recalling firm | Stryker Neurovascular |
|---|---|
| Manufacturer | Not disclosed in the FDA record. |
| Brand name | Not disclosed in the FDA record. |
| Product description | Trevo NXT ProVue 3 x 32, US, Catalog: 90312 Kits: TREVO NXT 3X32+TRAK21 2-PACK - CE, Catalog: 91412 TREVO NXT 4X28+TRAK21 2-PACK - CE, Catalog: 91413 TREVO NXT 4X41+TRAK21 2-PACK - CE, Catalog: 91414 TREVO NXT 6X37+TRAK21 2-PACK - CE, Catalog: 91415 TREVO NXT 3X32+PRO14 2-PACK - CE, Catalog: 91416 TREVO NXT 4X28+TRAK21+CAT6 3-PACK - CE, Catalog: SFP914170 TREVO NXT 6X37+TRAK21+CAT6 3-PACK - CE, Catalog: SFP914190 |
| Classification | Class II |
| Recall number | Z-1905-2024 |
| Report date | Not disclosed in the FDA record. |
| Status | Ongoing |
| Reason for recall | Neurovascular devices did not meet the minimum sample size required for endotoxin testing during manufacturing processes and are out of compliance with the AAMI ST72 standard, so these devices may exceed the acceptable limits of endotoxin levels; high levels of endotoxins may increase the risk of fever, shock and aseptic meningitis. |
What this classification means
A Class II recall is FDA’s middle classification. FDA assigns Class II when use of, or exposure to, the recalled product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. FDA still requires the recalling firm to notify affected accounts and submit status reports on the correction, though the monitoring intensity is lower than for a Class I recall. FDA's Center for Devices and Radiological Health (for devices) or Center for Drug Evaluation and Research (for drugs) reviews the classification and can require additional corrective action if the initial response is judged insufficient. Because this record is filed as Class II, professionals and consumers handling an affected lot should treat FDA's own classification -- not this page's summary of it -- as the authoritative risk signal. A Class I recall is FDA’s most serious classification. FDA assigns Class I when there is a reasonable probability that use of, or exposure to, the recalled product will cause serious adverse health consequences or death. This classification does not mean harm has already occurred in every case -- it reflects FDA’s assessment of the realistic worst-case risk profile of the defect described in the recall, based on the reason for recall reported by the firm. Class I recalls receive the closest FDA monitoring of the three classes: the recalling firm typically must submit a recall strategy, periodic status reports, and effectiveness checks confirming that the affected lots have actually been removed from distribution or corrected in the field.
What consumers should do
Facilities, clinicians, and consumers holding an affected unit or lot of Trevo NXT ProVue 3 x 32, US, Catalog: 90312 Kits: TREVO NXT 3X32+TRAK21 2-PACK - CE, Catalog: 91412 TREVO NXT 4X28+TRAK21 2-PACK - CE, Catalog: 91413 TREVO NXT 4X41+TRAK21 2-PACK - CE, Catalog: 91414 TREVO NXT 6X37+TRAK21 2-PACK - CE, Catalog: 91415 TREVO NXT 3X32+PRO14 2-PACK - CE, Catalog: 91416 TREVO NXT 4X28+TRAK21+CAT6 3-PACK - CE, Catalog: SFP914170 TREVO NXT 6X37+TRAK21+CAT6 3-PACK - CE, Catalog: SFP914190 should stop using it for the purpose described in the recall notice and hold remaining stock pending instructions from Stryker Neurovascular. FDA recall records typically direct the recalling firm to notify known accounts directly with a recall letter describing the specific corrective action -- replacement, field correction, refund, or return. Anyone who received the product through a distributor rather than directly from Stryker Neurovascular should confirm with their supplier whether their specific lot or unit is on the affected list, since recall notices are lot- or unit-specific and not every unit of a product line is necessarily included. Questions about a specific unit's status should go to Stryker Neurovascular directly or to the distributor that supplied it; Argus HQ is a public-record aggregator, not the recalling firm, and cannot confirm individual unit status.
Stryker Neurovascular’s FDA history
Argus HQ has recorded 14 total FDA actions tied to Stryker Neurovascular: 0 warning letters, 14 recalls, 0 approval records, and 0 Form 483 inspection citations.
Frequently asked questions
- Has Stryker Neurovascular had other FDA recalls or enforcement actions?
- Yes. Argus HQ has recorded 14 total FDA actions tied to Stryker Neurovascular, including 14 recalls and 0 warning letters.
- What is the FDA recall number for this event?
- FDA recall number Z-1905-2024.
- What is the current status of this recall?
- Status as recorded by FDA: Ongoing.
- Where can I verify this recall directly with FDA?
- The verbatim FDA record is the source of truth for every recall Argus HQ tracks — always confirm against fda.gov before acting.
Know if this happens again — we'll email you.
Free. No spam, just recall alerts for what you tell us to watch.
Related enforcement actions
Full FDA history for Stryker Neurovascular- Recall: Stryker Neurovascular — Class II recall: The Trevo Trak 21 Microcatheter is a single-lumen, braided shaft, variable stiff… →
- Recall: Stryker Neurovascular — Class II recall: The Synchro2 Guidewires are a steerable guidewire family with a shapeable tip an… →
- Recall: Stryker Neurovascular — Class II recall: The Synchro SELECT Guidewires are a steerable guidewire family with a shapeable… →
- Recall: Stryker Neurovascular — Class II recall: The Synchro Neuro Guidewires are a steerable guidewire family with a shapeable t… →
- Recall: Stryker Neurovascular — Class II recall: DAC 044 115cm, Catalog: 90760 →
- Recall: Stryker Neurovascular — Class II recall: Trevo XP ProVue Retriever 4 x 20, Catalog: 90182 Trevo XP ProVue Retriever 3 x… →
- Recall: Stryker Neurovascular — Class II recall: FlowGate2 8F x 85cm, Catalog: 90485 FlowGate2 8F x 95cm, Catalog: 90495 →
- Recall: Stryker Neurovascular — Class II recall: Trevo Pro 14 Microcatheter, Catalog: 90231; Trevo Pro 18 Microcatheter, Catalog… →
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2024). FDA Recall Database: Class II Recall: Trevo NXT ProVue 3 x 32, US, Catalog:… by Stryker Neurovascular. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/recall/stryker-neurovascular-z-1905-2024-2024-06-05
"FDA Recall Database: Class II Recall: Trevo NXT ProVue 3 x 32, US, Catalog:… by Stryker Neurovascular." Argus HQ Research, Digital Empire Holdings LLC, 2024, argushq.ai/recall/stryker-neurovascular-z-1905-2024-2024-06-05.
Argus HQ Research. "FDA Recall Database: Class II Recall: Trevo NXT ProVue 3 x 32, US, Catalog:… by Stryker Neurovascular." Digital Empire Holdings LLC. Accessed August 27, 2026. https://argushq.ai/recall/stryker-neurovascular-z-1905-2024-2024-06-05.
@misc{argushq_argushq_ai_recall_stryker_neurovascular_z_1905_2024_2024_06_05_2024,
title = {FDA Recall Database: Class II Recall: Trevo NXT ProVue 3 x 32, US, Catalog:… by Stryker Neurovascular},
author = {{Argus HQ Research}},
year = {2024},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/recall/stryker-neurovascular-z-1905-2024-2024-06-05},
note = {Accessed: August 27, 2026}
}Source: FDA.gov — Recalls ↗

